Introduction: A precise prognostication of non-Hodgkin's lymphomas associated with hepatitis C virus (HCV) infection is not well established; particularly, the impact of liver toxicity after (immuno)-chemotherapy on the outcome of pts with HCV+ NHL is not fully clarified. Methods: We analysed clinical and virological features, toxicity and prognosis of 1,123 pts with HCV+ NHL diagnosed from 1993 to 2010 in 15 Italian institutions. Results: 555 cases were DLBCL, 551 indolent NHL (286 MZL) and 17 T-NHL; all pts were HIV-, 91% were HCV-RNA+ and 2.5% carried HBsAg. An (immuno)-chemotherapy regimen was administered as 1 st line treatment in 922 pts (31% with reduced dose): 576 received a CHOP-like regimen (+ Rituximab in 271), 76 a III rd generation regimen, 187 alkylators, 30 purine analogues, 31 other regimens, 22 R alone. Overall, 357 pts received Rituximab. 37 pts with indolent NHL were treated with 1 st line anti-HCV antiviral therapy, 14 of whom obtained both a complete virologic and haematological response. Overall, 100 out of 729 evaluable pts (14%; 15% of DLBCL and 12% of indolent NHL) developed severe hepatic toxicity , that lead to withdrawal of therapy in 29 pts. Use of Rituximab was not associated with increased rate of severe liver toxicity (p=0.5); particularly, in DLBCL R-CHOP and CHOP showed the same rate of severe hepatic toxicity (15%, p=ns). After a median F-UP of 2.7 years, 348 pts died (24 for liver failure). 5-yr OS was 76% for indolent NHL and 62% for DLBCL. In DLBCL IPI and R-IPI were predictive of OS (p<0.001). Parameters associated with a shorter OS according to stepwise Cox regression analysis in indolent NHL and DLBCL are shown in Table 1 . In indolent NHL, antiviral treatment either as 1 st line and/or as subsequent therapy conferred a significant OS advantage (p=0.008). We combined the 3 factors significantly associated to a worse OS in DLBCL (ECOG, albumin, HCV-RNA load) in a new HCV Prognostic Score (HPS) able to discriminate 3 risk categories (low=0; intermediate=1; high risk ‡2 factors, p<0.001). After adjusting by IPI in multivariate Cox analysis, HPS retained prognostic effect (p<0.001), while IPI itself did not. Conclusions: A significant proportion of pts with HCV+ NHL, when treated with conventional (immuno)-chemotherapy, develops severe liver toxicity. In indolent NHL, antiviral therapy at any time during lymphoma history ameliorates OS. In HCV+ DLBCL, the addition of rituximab to CHOP does not seem to increase hepatic toxicity; moreover, the new HPS score performs better than IPI in discriminating different risk categories. Results: All IPI factors but extra-nodal involvement had an independent significance in the MVA. The sub-analysis of the 641 patients ages <= 60 years, gender had a borderline significance (p=0.05) with poorer overall survival (OS) in the male patients.
Introduction: A precise prognostication of non-Hodgkin's lymphomas associated with hepatitis C virus (HCV) infection is not well established; particularly, the impact of liver toxicity after (immuno)-chemotherapy on the outcome of pts with HCV+ NHL is not fully clarified. Methods: We analysed clinical and virological features, toxicity and prognosis of 1,123 pts with HCV+ NHL diagnosed from 1993 to 2010 in 15 Italian institutions. Results: 555 cases were DLBCL, 551 indolent NHL (286 MZL) and 17 T-NHL; all pts were HIV-, 91% were HCV-RNA+ and 2.5% carried HBsAg. An (immuno)-chemotherapy regimen was administered as 1 st line treatment in 922 pts (31% with reduced dose): 576 received a CHOP-like regimen (+ Rituximab in 271), 76 a III rd generation regimen, 187 alkylators, 30 purine analogues, 31 other regimens, 22 R alone. Overall, 357 pts received Rituximab. 37 pts with indolent NHL were treated with 1 st line anti-HCV antiviral therapy, 14 of whom obtained both a complete virologic and haematological response. Overall, 100 out of 729 evaluable pts (14%; 15% of DLBCL and 12% of indolent NHL) developed severe hepatic toxicity (WHO grade [3] [4] , that lead to withdrawal of therapy in 29 pts. Use of Rituximab was not associated with increased rate of severe liver toxicity (p=0.5); particularly, in DLBCL R-CHOP and CHOP showed the same rate of severe hepatic toxicity (15%, p=ns). After a median F-UP of 2.7 years, 348 pts died (24 for liver failure). 5-yr OS was 76% for indolent NHL and 62% for DLBCL. In DLBCL IPI and R-IPI were predictive of OS (p<0.001). Parameters associated with a shorter OS according to stepwise Cox regression analysis in indolent NHL and DLBCL are shown in Table 1 . In indolent NHL, antiviral treatment either as 1 st line and/or as subsequent therapy conferred a significant OS advantage (p=0.008). We combined the 3 factors significantly associated to a worse OS in DLBCL (ECOG, albumin, HCV-RNA load) in a new HCV Prognostic Score (HPS) able to discriminate 3 risk categories (low=0; intermediate=1; high risk ‡2 factors, p<0.001). After adjusting by IPI in multivariate Cox analysis, HPS retained prognostic effect (p<0.001), while IPI itself did not. Conclusions: A significant proportion of pts with HCV+ NHL, when treated with conventional (immuno)-chemotherapy, develops severe liver toxicity. In indolent NHL, antiviral therapy at any time during lymphoma history ameliorates OS. In HCV+ DLBCL, the addition of rituximab to CHOP does not seem to increase hepatic toxicity; moreover, the new HPS score performs better than IPI in discriminating different risk categories. Results: All IPI factors but extra-nodal involvement had an independent significance in the MVA. The sub-analysis of the 641 patients ages <= 60 years, gender had a borderline significance (p=0.05) with poorer overall survival (OS) in the male patients.
When beta2microglobolin was introduced in the model (with all IPI factors) a highly significant importance was seen. Also decreased albumin was of prognostic importance, whereas lymphocyte count was not and the stage was no longer of significant importance. Conclusion: EN involvement is not of significant importance in the prognostic model. Albumin and beta2microglobulin should be included as prognostic markers in a revision of IPI, leaving out EN involvement and stage. Interestingly, a border significant difference in OS in benefit of female gender was found supporting the hypothesis that gender may be of importance, particularly in younger DLBCL patients. Background: Burkitt lymphoma (BL) is a rare neoplasm constituting 1-2% of adult Bcell lymphomas in the western world. Prognostic models and chemotherapy regimens have primarily been developed for the paediatric patient population and standard treatment for adult BL is still not defined. Our aims in this study were to establish prognostic factors for overall survival in adult BL and evaluate the efficacy of different chemotherapy regimens in a population based setting. Methods: Our study population was collected from the Swedish Lymphoma Registry 2000-2010. During this period, 156 adult patients with BL were identified. Results: Age and WHO performance status (PS) were statistically significant adverse prognostic factors for overall survival in multivariate analysis, and S-LDH was associated with adverse outcome in univariate analysis. In addition, there was a trend towards inferior overall survival in females (p=0.054).
PROPOSAL OF A MODIFIED PROGNOSTIC INDEX FOR ADULT
A modified prognostic index, based on: age >40 years, PS >1, and LDH >ULN was proposed, separating the population in three distinct groups. Patients with a score of 0-1, 2 and 3 were found to have a 2-year survival of 91.2%, 58.4% and 27.5%, respectively.
High-intensity therapy regimens, i e BFM protocols or Hyper-CVAD were associated with more favourable outcome (2-year survival 80% and 78.6%), compared to patients receiving CHOP or other regimens (2-year survival 62.3% and 33%), although this could largely be explained as being due to differences in patient age.
Rituximab addition was not significantly associated with improvement in survival (HR=0.8, 95% C. I. 0.5-3.0). Conclusion: Prognostic factors of importance for adult BL differ slightly from other aggressive lymphomas and a modified staging scheme may be valuable, as proposed. Further population based studies and/or randomised trials need to be performed to define standard treatment for adult BL. rd Tri). 11 pts received non-anti-metabolite cytotoxic Ctx (n=10) or radiotherapy (RT) (n=1), which was initiated in the 2 nd Tri in the majority (Table 1) . Ctx was continued to allow a ''nearterm'' delivery. Further, delivery was planned >3-4 weeks after the final intra-partum Ctx cycle. The overall response rate was 91% (CR 81%). Overall, pts delivered at a median of 37 wks (34-40) (induction of labor 39% and cesarean section rate 17%). Minimal complications occurred (pre-eclampsia and gestational diabetes 6% each; no chorioamnionitis). The mean birthweight of infants (n=18) was 2.8 Kg. None of the infants with available data (n=16) had any birth defects or developmental sequelae. With median follow-up of 36 months (12-137) for all pts, the 3-year PFS was 86% and 3-year OS rate of 95%. Conclusions: Our report confirms that standard chemotherapy can be used safely during the 2 nd /3 rd Tri's and that an individualized therapeutic approach is associated with excellent maternal and fetal outcomes. There was a significant excess of ABC phenotype in the EBV positive cases, p=0.001. CD30 was frequently positive (88% of cases). Nineteen patients were treated with CHOP or CHOP like anthracycline based therapy, 13 included rituximab. Seven received radiotherapy in addition. One patient had tumour resection only. The remaining patients received palliative treatment. Seven patients died within a year of diagnosis, 6 secondary to lymphoma and 1 from infection. Most of these cases were deemed unsuitable for chemotherapy due to comorbidities. Overall survival at 5 years was influenced by patient age (75% for <60yrs, 50% for >60yrs) and treatment (CHOP/CHOP like 64.4%, other 37.5%). There was a trend toward improved overall survival in the EBV+ DLBC group, p=0.058. Conclusion: EBV positive DLBCL of the elderly has a wide morphological spectrum and frequently affects the upper aerodigestive tract. Previously thought of as a disease with poor prognosis, we have demonstrated that patients with this entity in the West of Scotland have a similar outcome to EBV negative DLBCL. 
HEMATOLOGICAL AND VIROLOGICAL FEATURES OF NON-HODGKIN'S LYMPHOMAS ASSOCIATED WITH HEPATITIS C VIRUS

Introduction:
The association between hepatitis C virus (HCV) infection and nonHodgkin's lymphomas (NHL) has been demonstrated in epidemiological studies. HCV infection is still a public health problem; in Lombardia, a densely populated region of northern Italy with around 10 millions of inhabitants, the prevalence of infected people is around 5%. In order to study the features of HCV-related NHL, we pursue a prospective multicentric observational study in Lombardia. We present here the characteristics and evolution of the patients (pts) included in this study.
Methods: Since January 2008 we collected histological, clinical and therapeutic data of 218 consecutive pts with NHL and HCV infection, diagnosed in Hematology Centres of the ''Rete Ematologica Lombarda'' (Lombardy Hematology Network). This prospective observational study (Registro Lombardo dei Linfomi HCV-positivi) was approved by the Regional Administration and by IRBs of participating institutions. All pts signed a written informed consent.
Results: Males/females ratio was 87/131; median age at diagnosis was 68 yrs (range 36-84). Histotypes were: 99 DLBCL, 57 MZL (19 splenic, 13 nodal, 25 extranodal of MALT), 22 follicular lymphoma, 6 small lymphocytic lymphoma, 6 lymphoplasmocytic lymphoma, 2 mantle cell lymphoma, 26 low-grade B-cell lymphoma NOS. Ann Arbor stage was III-IV in 171, with bone marrow involvement in 96; ECOG score was ‡ 2 in 34. 133 pts showed at least one extranodal localization (spleen in 42, skin in 25, Waldeyer's ring in 10, ocular adnexa in 8). Virological data are summarized in Table 1 . Presence of serum MC (p=0.003), autoimmunity (p<0.001), cryoglobulinemia (p=0.005) were statistically associated with indolent NHL. 144 pts had a known HCV-positivity before the diagnosis of NHL and 40 pts (28%) were treated with antiviral therapy. Data on treatment were available in 201 pts. 151 pts received chemotherapy (in 97 with Rituximab). A grade 3-4 WHO liver toxicity developed in 12 pts and 5 pts interrupted the treatment. Pts with liver toxicity and/or drug reduction of dosage and/or early interruption of therapy showed a worse OS (p=0.01) and PFS (p=0.03).
Conclusions:
In this prospective collection of data within a regional hematology network most frequently reported histologies are DLBCL and MZL. In a significant proportion of indolent and aggressive lymphoma pts, first detection of HCV infection is concurrent to lymphoma diagnosis. HCV infection seems to hamper, in a significant subset of cases, full dose administration of (immuno)-chemotherapy. Introduction: Previous studies have demonstrated a positive relationship between BMI and risk of death from non-Hodgkin lymphoma (NHL). It remains unclear if obesity causes an increase in NHL incidence, increased mortality after NHL diagnosis, or both. Using a retrospective cohort of DLBCL patients in the United States Veterans Health Administration (VHA) database, we evaluated the influence of BMI at the time of diagnosis on overall survival (OS). To our knowledge, this represents the largest cohort of patients with DLBCL not treated in a clinical trial in whom the relationship between BMI and OS has been evaluated, and the only one with data from the post-rituximab era. Methods: Records of patients diagnosed with DLBCL between October 1998 and September 2008 were identified in the VHA cancer registry. Data was obtained on patient demographics, date of diagnosis, stage, co-morbidities, height, weight, and International Prognostic Index (IPI). Co-morbidities were converted into a single score using the Charlson index. Of 3,052 HIV negative patients, 2,455 patients (80%) had complete information, with the exception of IPI.IPI was available on a subset of 507 patients (21%). Results: Mean patient age was 67.4 years, 97% were men, with 26%, 17%, 20% and 38% stages I, II, III, and IV, respectively. Cox modeling evaluated the impact of BMI on OS, controlling for age, stage, Charlson score, and year of diagnosis (an indirect measure of rituximab use). Compared to normal weight patients (BMI 18.5 to <25), underweight patients (BMI <18.5) had worse OS (HR 1.411, p=0.012), while overweight (BMI 25 to <30) and obese (BMI ‡ 30) patients had improved OS (HR = 0.709, p< 0.0001 and HR= 0.663, p< 0.0001, respectively). Older age, advanced stage, higher Charlson score, and earlier year of diagnosis were all associated with worse OS.In patients with IPI data, only underweight patients had a significant difference in baseline IPI compared to patients with normal BMI (mean = 3.14 vs. 2.23, p =0.019). A similar relationship between BMI and OS was observed in both the pre-and postrituximab eras. Conclusions: BMI in the overweight or obese range at time of DLBCL diagnosis was associated with significantly better OS, both pre-and post-rituximab. Possible reasons for the better prognosis in overweight and obese patients include: Better prognosis DLBCL phenotype, improved chemotherapy tolerence, or improved physiologic reserve. Understanding the reasons for the difference in prognosis may improve the understanding of the pathophysiology and/or treatment of DLBCL disease in obese and non-obese patients. Y-ibritumomab tiuxetan in 5 patients. In all cases, IFRT was delivered between the dosimetric and therapeutic doses of RIT, on non-consecutive days. The median age of patients treated was 61 (38 -82). The median number of prior therapies was 2 (1 -4) . The median size of persistent disease prior to treatment was 4.2 cm (2.5 -19.5). Results: With a median follow-up of 14 months (6 -21), 11/13 patients obtained a complete response to combined therapy and remain in remission at this time. No patients have failed within the IFRT fields. Two patients achieved a local CR but exhibited persistent disease outside the IFRT fields. Both of these patients underwent bone marrow transplant and died from complications of this therapy. All 13 patients tolerated combined IFRT and RIT very well with no toxicity from the addition of IFRT, and only transient grade 2-3 hematologic toxicity from the RIT. The progression-free survival (PFS) is 100% in patients achieving a CR and is 85% for all patients treated. Conclusion: The addition of IFRT to sites of active disease ‡ 2.5 cm to RIT in patients with relapsed/refractory B-cell lymphomas is well-tolerated, adds no toxicity to that of RIT alone, and results in excellent PFS, particularly for patients who obtain a CR. As the only failures to therapy were outside of radiation portals, the addition of IFRT to sites of active disease may play an important role in improving PFS when added to RIT. Prospective studies are needed to further evaluate this novel combined therapeutic approach. Correlative studies should be pursued to determine the mechanism of this improved tumor control. Background: In patients with diffuse large B-cell lymphoma (DLBCL), deaths during the first 2 years mostly reflect treatment failure or relapse. In the other hand, delayed deaths could be due to the return of the underlying mortality hazard (e.g. ageassociated morbidity). We aimed to analyze the 10 year outcome of patients included in the LNH98-5 study comparing CHOP to CHOP plus rituximab (R-CHOP) by focusing on the relative survival (RS). This new epidemiological approach compares the observed survival in the study population with the expected survival in the general population. Patients and Methods: LNH98-5 was a randomized study that included 399 previously Follow up data was updated in July 2009. The RS probabilities were estimated using the mortality rates published by INSEE [http//www.insee.fr/]. RS are computed as the ratio between overall survival (OS) in the study population and the expected survival in the general population matched for age and gender. Results: Overall, the 10-yr OS rate was 35% and the 10-yr RS rate was 48%. Since there was a treatment effect of R-CHOP on 10-yr OS (44 vs 28%, P = 0.004), its impact was tested in term of RS. The difference between R-CHOP and CHOP in 10-yr RS was also significant (56 vs 38%, P = 0.0013).
TEN YEARS RELATIVE SURVIVAL ANALYSIS OF THE
More patients died from causes unrelated to lymphoma or its treatment in the R-CHOP arm: cancer (9% in both arms) and other diseases (21 and 11%, respectively) mainly cardiovascular diseases (16 vs 10%, respectively) but no pattern emerged, as most of the underlying conditions related to the death were present before the diagnosis of DLBCL.
Lastly, the annual relative mortality rate was estimated at 1% after the fifth years in patients receiving R-CHOP. Conclusion: Combination of rituximab plus CHOP allows a large improvement of the 10-yrsRSin elderly patients. However, there remains an excess of mortality when compared with the general population. In long-term survivors, we recommend a secondary prophylaxis for the well-known risks factors of cancer and cardiovascular diseases. + aggressive B-cell lymphoma were recruited and are evaluable (median age 68 years; IPI=1: 30%, IPI=2: 28%, IPI=3: 26%, IPI=4,5: 16%). There was no difference between the four arms with respect to long-term toxicity and second neoplasms. As by intention to treat, the 7-year EFS rate was 33% after 6xCHOP-14 (n=307), 40% after 8xCHOP-14 (n=305), 50% after 6xR-CHOP-14 (n=306), and 52% after 8xR-CHOP-14 (n=306). After a median observation time of 82 months, the estimated 7-year overall survival (OS) rates were 50% for 6xCHOP-14, 52% for 8xCHOP-14, 62% for 6xR-CHOP-14, and 60% for 8xR-CHOP-14. In a multivariate analysis using 6xR-CHOP-14 without rituximab as the reference and adjusting for the stratification variables elevated LDH, advanced stage III&IV, ECOG performance state >1, bulky disease, >1 extranodal site, and age >70, both rituximab arms had a significantly improved EFS (6xR-CHOP-14: RR=0.5, p<0.001; 8xR-CHOP-14: RR=0.5, p<0.001), PFS (6xR-CHOP-14: RR=0.5, p<0.001; 8xR-CHOP-14: RR=0.5; p<0.001) and OS (6xR-CHOP-14: RR=0.6; p<0.001; 8xR-CHOP-14: RR=0.7; p=0.004). Conclusions: In contrast to the 3-year follow-up, not only 6xR-CHOP-14, but also 8xR-CHOP-14 achieved a significantly better overall survival compared to 6xCHOP-14 after a median observation time of 82 months. With respect to all endpoints, 6xR-CHOP-14 was slightly, but not significantly better than 8xR-CHOP-14. Therefore, due to its lower toxicity and shorter time under chemotherapy (6xCHOP-14: 10 weeks, 8xCHOP-14: 15 weeks, and 8x-CHOP-21 even 21 weeks plus 1 day), 6xCHOP-14 in combination with 8 applications of rituximab is the preferred regimen for elderly patients with CD20
7-YEAR FOLLOW-UP OF THE RICOVER-60 TRIAL OF THE GERMAN HIGH-GRADE NON-HODGKIN LYMPHOMA STUDY GROUP (DSHNHL)
+ aggressive lymphomas. Supported by Deutsche Krebshilfe. Background: Rituximab has improved prognosis in DLBCL, however OS for high IPI patients is only 58%. In order to improve outcome, ASCT is still considered in some prospective trials. The aim of our study is to assess the role of early PET to descalate treatment and avoid transplant in patients PET negative after 3 courses. Patients and Methods: A prospective non-randomised phase II trial (EudraCT: 2006-005254-68) was undertaken in 20 centers. Primary endpoint was progression-free-survival (PFS). Only aIPI>1 or 1 with a High beta 2 were included. All patients received 3 R-MegaCHOP. A PET scan was performed at diagnosis and after the third cycle; Pts with PET -received 3 more R-MegaCHOP cycles; Pts with PET+ received early salvage therapy with 2 R-IFE cycles and those in PR or CR underwent ASCT with BEAM. Results: A total of 73 pts were included. Median age was 54 years (25-65). 66 pts were evaluated after 3 cycles of R-MegaCHOP: 54.5% achieved CR (PET -) and received 3 more R-MegaCHOP without transplant; 0,7 % progressed; 44.9% (PET +) received R-IFE and ASCT. 91.6% of the early PET -group completed 6 cycles of chemotherapy and 89.6% of the early PET + group received the R-IFE and ASCT. A median follow-up of 19 months, 3-year PFS and OS in an intention to treat analysis were 68% and 77% respectively. 3-year PFS and OS were 79% and 87% in the R-MegaCHOP (6 relapses, 4 deaths), and 59% and 73% in the R-IFE/ASCT arm (6 progressions, 6 deaths) (p>0.1 in both groups). Comments: Our preliminary results show that, in patients with unfavourable DLBCL, good results could be obtained after induction with R-MEGACHOP with or without ASCT; a treatment deescalation based on early PET could be an option, with ASCT only for patients with a slower response. Treatment plan was: 6 RCHOP21 in association with L days 1-14 at the established dose level. Phase I was planned to define the Maximum Tolerated Dose (MTD) that is the dose that achieves a DLT in 33% or less patients; evaluation was planned after 3 LRCHOP. Study was designed with the Continual Reassessment Method (CRM), a Bayesian memory design that uses, as dose allocation rule of the sequentially incoming patients, the re-estimated probability of toxicity based on the results obtained for the patients already observed. Four doses of L were tested: 5, 10, 15 and 20 mg. At the end of each cohort, the dose level associated with an updated DLT probability closest to 33% was recommended to be administered to the next cohort. International Prognostic Index (IPI), dose intensity, toxicity, response and outcomes were assessed. Results: Sixty two patients treated with DA EPOCH+/-R were identified. Of those, 41 (66%) were male. The median age was 53 (range 17-87) years. Only 2 patients received this regimen in the relapsed setting. The majority (73 %) of patients had diffuse large B cell lymphoma, while other diagnoses included primary mediastinal B cell lymphoma, transformed lymphoma, Burkitt's lymphoma, and Plasmablastic lymphoma. Seventy percent of patients had stage IIB or higher disease; in fact 49% had stage IV disease. Twenty seven patients (44%) had an IPI of three or more. A median of 6 (range 1-6) cycles were administered. In total, 312 cycles were administered; dose intensity was achieved in 77% of cycles. Fifty-nine patients were evaluable for response. 73% of patients achieved CR and 14% PR. Of those with a low IPI score (£2), 88% responded. In the high IPI group (>2), 77% responded. 65% of cycles resulted in grade 3/4 haematological toxicity. Grade 3/4 non-hematological toxicity was seen in 9% of cycles. Conclusion: While we eagerly await the results of the CALGB study, we demonstrate that DA EPOCH +/-R may be administered safely outside of clinical trials, with reproducible outcomes and acceptable toxicity. with a median age of 57 years (range, 20 -72) presented with involvement of more than one extranodal site in 7 cases, and paravertebral lesions with contact to the meningeal sack in 2 cases. Moreover, IPI ‡4 and elevated LDH were present in 5 and 6 patients, respectively. HD-MTX cycles were interspersed 14 days after R-CHOP cycles. Ideally, the following scheme was adopted: d1 = R-CHOP, d15 = HD-MTX, d22 = R-CHOP, d36 = HD-MTX, d43 = R-CHOP, and so on. HD-MTX was given at 4 g/m 2 as 4 hour infusion with intensive hydration and standard folinic acid rescue. Results: Overall, a total of 52 R-CHOP and 27 HD-MTX cycles (1 patient is still undergoing treatment) were administered with a median of 3 HD-MTX cycles (range, 2-4) for each patient. The median interval between 2 R-CHOP cycles encompassing a HD-MTX cycle was 22 days (range, 20 -38). The treatment was well tolerated without significant toxicity. One week after the HD-MTX cycles, i.e. immediately before the following R-CHOP cycles, median white blood cell and platelet counts were 4,4 x 10 9 /L (range, 1,6 -9,7) and 245 x 10 9 /L (range, 89 -569), respectively. Leukocytopenia and thrombocytopenia of any grade due to HD-MTX occurred in 21% and 0%, respectively. None of the patients suffered renal toxicity. Disappointingly, two relapses occurred 2 and 10 weeks after completion of treatment. Conclusions: Although small, this study shows that intercalating standard R-CHOP treatment with 2 to 4 cycles of HD-MTX is feasible without disrupting dose density of the R-CHOP21 scheme and without adding significant toxicity. However, CNS relapses occurred, suggesting that this approach may not be sufficient to prevent CNS disease in all patients. A larger study in selected high-risk patients is now justified in order to clarify whether a reduction of CNS involvement can be achieved by adding HD-MTX to R-CHOP. Background: The incidence of NHL rises exponentially with age and this is the most rapidly growing segment of society. Further, patients (pts) > age 80 years are underrepresented in clinical trials and data on their disease characteristics and outcome is sparse. Methods: A multicenter retrospective review of pts ‡ 80 with an initial diagnosis of NHL (1999 -2009) was completed. Co-morbidities were scored using the Cumulative Illness Rating Scale for Geriatrics (CIRS-G). Presence of geriatric syndromes at initial diagnosis (dx) were collected along with activity of daily livings (ADLs). Results: 303 pts were identified [170 aggressive (143 B-cell), 133 indolent (109 B-cell)]. DLBCL was the most common (74%) aggressive (Agg) NHL. Follicular NHL was the most common (25%) indolent (Ind) histology. Median age was 83.5 (80-95) with 45% males, stage III/IV in 52%, high LDH in 39%, and reduced renal function in 23%. Notably, 31% of pts had prior malignancy, the majority of which had prior radiation. Only 6% had > 1 extranodal site and 11% had bulky disease (> 5 cm). In terms of geratric assessments, ‡1 geriatric syndrome was present in 26% (dementia most common: 25%), non-fit classification in 30%, while 14% had loss of ADLs. Further, 18% of pts had a grade 4 CIRS-G in at least 1 category. Pts with Agg B-cell received rituximab (R) based therapy in 66%; 40% had dose reductions/delays, despite use of growth factors in 68%. For Ind B-cell pts, 39% were 'observed' for a median of 26 months; when treated (Tx), 44 received a R-based regimen. Collectively in Agg NHL, the overall response rate (ORR) was 65% (44% CR), while when Tx, the ORR for Ind NHL was 60% (32% CR). At 49-month median follow-up (6-149), 4-year progression-free survival (PFS) and overall survival (OS) for Agg NHLs were 31% and 44%, respectively (stage I/II: PFS 53%, OS 66% vs stage III/IV: PFS 20%, OS 32%; p=<0.0001 and 0.0002, respectively). 4-year PFS and OS for all Ind NHLs were 44% and 66%, respectively, with no survival differences noted between stages. Additionally, no differences in PFS or OS were seen comparing CLL vs CTCL vs other Ind NHL histologies. Prognostic factors were identified (Table) . Multivariate cox regression for Agg NHL showed that stage III/IV, ADL loss, and < CR correlated with PFS and OS, while the latter 2 were significant factors for Ind NHL.
TREATMENT DESCALATION BASED ON EARLY FDGPET IN PATIENTS WITH POOR RISK DIFFUSE LARGE B CELL LYMPHOMA (DLBCL). A PROSPECTIVE PHASE II GELTAMO TRIAL
LENALIDOMIDE PLUS RITUXIMAB-CHOP21 IN ELDERLY
ALTERNATING HIGH-DOSE METHOTREXATE
EARLY DEATH IN PATIENTS DIAGNOSED WITH NON-HODGKIN'S LYMPHOMA
Conclusions: Geriatric assessment tools, including CIRS and ADLs, are powerful predictors of outcome and complement more standard prognostic features. Incorporation of geriatric prognostic models should be prospectively studied. 
